Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 8/20 | 0.41 |
| ▸ | CES1 | P23141 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019991 | 0.85 | CA1 (0.58) | CA1CA2CA4CES2CES1 | |
| SCHEMBL17322555 | 0.82 | CA1 (0.45) | CA1CA2CA4CES2CES1 | |
| SCHEMBL8072641 | 0.82 | ALDH1A1 (0.43) | CA1CA2CA4CES2CES1 | |
| SCHEMBL30417635 | 0.80 | CA1 (0.43) | CA1CA2CA4CES2CES1 | |
| SCHEMBL17372335 | 0.80 | POLB (0.38) | CA1CA2CA4CES2CES1 | |
| SCHEMBL5506097 | 0.80 | CA1 (0.43) | CA1CA2CA4CES2CES1 | |
| SCHEMBL364018 | 0.78 | CA1 (0.50) | CA1CA2CA4CES2CES1 | |
| SCHEMBL9693376 | 0.78 | CA1 (0.50) | CA1CA2CA4CES2CES1 | |
| SCHEMBL8927424 | 0.77 | CA1 (0.36) | CA1CA2CA4CES2CES1 | |
| SCHEMBL8926676 | 0.77 | CA1 (0.36) | CA1CA2CA4CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| CN-109293478-B | Method for preparing tetrafluorobenzyl alcohol | 大连奇凯医药科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-9422231-B2 | Method for inhibiting Trypanosoma cruzi | HOWARD UNIVERSITY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150073177-A1 | METHOD FOR INHIBITING TRYPANOSOMA CRUZI | HOWARD UNIVERRSITY (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140336187-A1 | METHODS FOR TREATING LEISHMANIASIS | HOWARD UNIVERSITY | 2014-11-13 | — | — | US | disclosed |
| WO-2013074930-A1 | METHODS FOR TREATING LEISHMANIASIS | HOWARD UNIVERSITY (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013016661-A1 | METHOD FOR INHIBITING TRYPANSOMA CRUZI | HOWARD UNIVERSITY (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-0312085-B1 | NOVEL QUINOLINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND ANTIBACTERIAL AGENT CONTAINING THEM | Dainippon Pharmaceutical Co., Ltd. (JP) | 1993-05-12 | — | — | EP | disclosed |
| US-5164392-A | Active against streptococci and staphylococci | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1992-11-17 | — | — | US | disclosed |
| US-5013841-A | Oxo quinoline derivatives | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1991-05-07 | — | — | US | disclosed |
| EP-0312085-A2 | Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them | Dainippon Pharmaceutical Co., Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336187-A1 | METHODS FOR TREATING LEISHMANIASIS | LSS, CYP51A1, NQO1 | CA1 4836/4885CA2 3627/4885CA4 3599/4885 |
| US-20150073177-A1 | METHOD FOR INHIBITING TRYPANOSOMA CRUZI | PCNA, NQO1, NQO2 | CA1 4673/4885CA2 3795/4885CA4 4106/4885 |
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | CA1 1987/4885CA2 4078/4885CA4 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.